Skip to main content
. 2020 Mar 11;10:4484. doi: 10.1038/s41598-020-61416-1

Figure 2.

Figure 2

Changes in sTK1 activity levels during systemic therapy. Changes in log sTK1 levels from baseline to 1, 3 and 6 months during systemic therapy for all patients (a) and for subgroups based on treatment regimen; chemotherapy (b) versus endocrine therapy (c). Red lines represent the median sTK1 levels in the respective groups.